In 2007, using data from the UK Myositis Network (UKMyoNet), Chinoy et al. [6] investigated the prevalence of anti-TIF1-Ab in IIM cases with and without cancer and reported that 50% of anti-TIF1-Ab-positive cases suffered from CAM. Here, TRIM24 is linked to cancer.